Anti-TNFalpha therapy for hidradenitis suppurativa. Results from a national cohort study between 2000 and 2013.
Fiche publication
Date publication
septembre 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François, Pr HUMBERT Philippe
Tous les auteurs :
Sbidian E, Hotz C, Seneschal J, Maruani A, Amelot F, Aubin F, Paul C, Beylot Barry M, Humbert P, Dupuy A, Caux F, Dupin N, Modiano P, Lepesant P, Ingen-Housz-Oro S, Mahe E, Bachelez H, Chosidow O, Wolkenstein P
Lien Pubmed
Résumé
Hidradenitis suppurativa (HS) is a frequent chronic inflammatory skin disease typically characterized by recurrent painful, deep inflammatory nodules of the axillary, breast, groin and gluteal areas. European recommendations are mainly based on expert opinion. Drug treatments are heterogenous (e.g., antibiotics, corticosteroids, retinoids) and lack consensus among expert centres. The most severe disease forms or those failing to respond to conventional drugs may be associated with worsened functional prognosis. Anti-tumor necrosis factor alpha (anti-TNFalpha) drugs have been prescribed in these cases. The results of randomized controlled trials (RCTs) are discordant. Three RCTs concluded to the efficacy of adalimumab (ADA), and two others did not detect any difference between infliximab (IFX) or etanercept (ETA) and placebo. Finally, data from the literature and reported experiences do not conclude on the efficacy of anti-TNFalpha drugs for HS. This article is protected by copyright. All rights reserved.
Référence
Br J Dermatol. 2015 Sep 25